Latigo Biotherapeutics, Inc. (LTGO) Stock Forecast & Price Target
LTGO Analyst Ratings
Strong Buy
3Buy0Hold0Sell
Based on 3 analysts giving stock ratings to Latigo Biotherapeutics, Inc. in the past 3 months
LTGO Stock 12 Month Forecast
Average Price Target
$57.67▲(313.38% Upside)Based on 3 Wall Street analysts offering 12 month price targets for Latigo Biotherapeutics, Inc. in the last 3 months. The average price target is $57.67 with a high forecast of $73.00 and a low forecast of $50.00. The average price target represents a 313.38% change from the last price of $13.95.
Past 12 Months12 Month ForecastJan2026Oct2026
High$73.00
Average$57.67
Low$50.00
Highest Price TargetHighest$73.00Average Price Target$57.67Lowest Price TargetLowest$50.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Analyst Profile | Expert Firm | Price Target | Position | Upside / Downside | Action | Date | Follow | Article |
|---|---|---|---|---|---|---|---|---|
| Salveen Richter | Goldman Sachs | $73 | buy | 423.30%Upside | Reiterated | 09/01/26 | ||
| Akash Tewari | Jefferies | $50 | buy | 258.42%Upside | Initiated | 09/01/26 | ||
| Yatin Suneja | Guggenheim | $50 | buy | 258.42%Upside | Initiated | 09/01/26 |
| Analyst Profile | Date | Price Target | Position | Upside / Downside | Action | Follow | Article | Expert Firm |
|---|---|---|---|---|---|---|---|---|
| Salveen Richter | 09/01/26 | $73 | buy | 423.30%Upside | Reiterated | Goldman Sachs | ||
| Akash Tewari | 09/01/26 | $50 | buy | 258.42%Upside | Initiated | Jefferies | ||
| Yatin Suneja | 09/01/26 | $50 | buy | 258.42%Upside | Initiated | Guggenheim |
Stocks with the Highest Top Analyst Consensus in the General Sector
Best Analysts Covering Latigo Biotherapeutics, Inc.
3 Months
Success Rate0/1 ratings generated profit
0%
Average Return
-37.30%
Copying Salveen Richter's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -37.30% per trade.
1 Year
Success Rate0/1 ratings generated profit
0%
Average Return
-37.30%
Copying Salveen Richter's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -37.30% per trade.
2 Years
Success Rate0/1 ratings generated profit
0%
Average Return
-37.30%
Copying Salveen Richter's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -37.30% per trade.
LTGO Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 0 | 0 | 3 | 3 | 3 |
In the current month, LTGO has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LTGO average Analyst price target in the past 3 months is 57.67.
LTGO Financial Forecast
LTGO Stock Forecast FAQ
What is LTGO’s average 12-month price target, according to analysts?
Based on analyst ratings, Latigo Biotherapeutics, Inc.’s 12-month average price target is $57.67.
What is LTGO’s upside potential, based on the analysts’ average price target?
Latigo Biotherapeutics, Inc. has 313.38% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is LTGO a Buy, Sell or Hold?
Latigo Biotherapeutics, Inc. has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is Latigo Biotherapeutics, Inc.’s price target?
The average price target for Latigo Biotherapeutics, Inc. is $57.67. This is based on 3 12-month price targets, issued in the past 3 months. The highest analyst price target is $73.00, the lowest forecast is $50.00. The average price target represents a 313.38% increase from the current price of $13.95.
What do analysts say about Latigo Biotherapeutics, Inc.?
Latigo Biotherapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Street analysts.
How can I buy shares of LTGO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.